Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Cara Therapeutics, Inc. (CARA)

Pharmaceutical Preparations

https://www.caratherapeutics.com

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

4 STAMFORD PLAZA, 107 ELM STREET 9TH FLOOR
STAMFORD, CT

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

01/31/2014

Market Cap

18,163,367

Shares Outstanding

54,480,000

Weighted SO

54,480,704

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

ZYNE --.--%

XXII --.--%

CRBP --.--%

CBDS --.--%

CBDS --.--%

CANN --.--%

CANN --.--%

Beta

0.6860

Last Div

0.0000

Range

0.24-3.06

Chg

0.0072

Avg Vol

906411

Mkt Cap

18163367

Exch

NASDAQ

Country

US

Phone

203 406 3700

DCF Diff

0.9548

DCF

11.0452

Div Yield

0.0000

P/S

1.6518

EV Multiple

0.2188

P/FV

1.5675

Div Yield %

0.0000

P/E

-0.1637

PEG

-0.0134

Payout

0.0000

Current Ratio

4.5938

Quick Ratio

4.4756

Cash Ratio

3.5421

DSO

37.2767

DIO

206.2062

Op Cycle

243.4829

DPO

0.0000

CCC

243.4829

Gross Margin

0.7354

Op Margin

-9.8145

Pretax Margin

-10.1019

Net Margin

-10.1019

Eff Tax Rate

-0.0073

ROA

-1.5323

ROE

-2.4131

ROCE

-1.8418

NI/EBT

1.0000

EBT/EBIT

1.0293

EBIT/Rev

-9.8145

Debt Ratio

0.1033

D/E

0.6456

LT Debt/Cap

0.3869

Total Debt/Cap

0.3923

Int Coverage

-159.6450

CF/Debt

-9.0101

Equity Multi

6.2506

Rec Turnover

9.7916

Pay Turnover

0.0000

Inv Turnover

1.7701

FA Turnover

1.5409

Asset Turnover

0.1517

OCF/Share

-1.2329

FCF/Share

-1.2915

Cash/Share

1.0346

OCF/Sales

-6.1357

FCF/OCF

1.0476

CF Coverage

-9.0101

ST Coverage

-401.5952

CapEx Coverage

-21.0115

Div&CapEx Cov

-21.0115

P/BV

1.5675

P/B

1.5675

P/S

1.6518

P/E

-0.1637

P/FCF

-0.2570

P/OCF

-0.2695

P/CF

-0.2695

PEG

-0.0134

P/S

1.6518

EV Multiple

0.2188

P/FV

1.5675

DPS

0.0000

Latest Headlines (EST)

Benzinga Dec 19, 07:30 Uber To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday Benzinga Dec 18, 14:23 Why Is Itch-Focused Cara Therapeutics Stock Trading Lower Today? Benzinga Dec 18, 14:23 Why Is Itch-Focused Cara Therapeutics Stock Trading Lower Today? Benzinga Nov 14, 07:38 Monday.Com To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday

Revenue Product Segmentation